A new phase II clinical trial is evaluating the safety and effectiveness of 212Pb-DOTAMTATE in patients who have somatostatin receptor-expressing neuroendocrine tumors but who have not received peptide receptor radionuclide therapy, or PPRT.
By Josh Mailman Being a NET patient usually means some amount of travel for our care. While the pandemic has negatively impacted almost every aspect
This year’s NET Cancer Day focused on the all-too-common experience of delayed diagnosis and misdiagnosis among those with neuroendocrine tumors. INCA, International Neuroendocrine Cancer Alliance,
Oncologist Mark Lewis, MD, discusses what we have learned about COVID-19 and NETs in the first six months of the pandemic in this video interview with NETRF CEO Elyse Gellerman.
Beginning in August, the NETWise podcast is putting together primary site-specific episodes. NETs can arise almost anywhere in the body, but most start in the gastrointestinal tract, lung, and pancreas.
Brian Bowe has weathered many storms: changes in his career, his marriage, and a tragic mass shooting. Looking back, he says one step helped him most in his recovery from neuroendocrine cancer: attending a support group.
NETRF Annual Report 2019 looks at scientific milestones and educational innovations. It includes stories about some of the people who have supported us to fund more research projects than ever before and offer new ways to learn about NETs.
Results find delays in care and treatment, fear of exposure to COVID-19 The Neuroendocrine Tumor Research Foundation (NETRF) recently surveyed NET patients and caregivers about
Recognizing the mental and emotional stresses of living with cancer during COVID-19 and limiting the impact on your thoughts, behavior, and mood.
Tom Bajoras, a West Coast musician is taking advantage of gaps in his schedule to compose music to support his and your journey with NETs.
